Tredegar (TG) 10-Q 2003 Q3 Quarterly report

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 10-Q

(Mark One)

|X| QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended September 30, 2003

OR

|_| TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from ____________________ to ____________________

Commission file number 1-10258

Tredegar Corporation
(Exact Name of Registrant as Specified in Its Charter)

Virginia
(State or Other Jurisdiction of
Incorporation or Organization) 54-1497771
(I.R.S. Employer
Identification No.)

1100 Boulders Parkway
Richmond, Virginia
(Address of Principal Executive Offices) 23225
(Zip Code)

Registrant's Telephone Number, Including Area Code: (804) 330-1000

        Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes |X| No |_|

        Indicate by check mark whether the registrant is an accelerated filer (as defined in Rule 12b-2 of the Exchange Act). Yes |X| No |_|

        The number of shares of Common Stock, no par value, outstanding as of October 31, 2003: 38,143,590.

PART I — FINANCIAL INFORMATION

Item 1. Financial Statements.

Tredegar Corporation
Consolidated Balance Sheets
(In Thousands)
(Unaudited)

	Sept. 30, 2003			Dec. 31, 2002
Assets
Current assets:
Cash and cash equivalents	$	94,850		$	109,928
Receivable from securities brokers		554			—
Accounts and notes receivable, net		99,576			92,892
Income taxes recoverable		54,895			12,863
Inventories		44,372			43,969
Deferred income taxes		8,789			20,976
Prepaid expenses and other		5,569			3,962
Total current assets		308,605			284,590
Property, plant and equipment, at cost		563,424			505,093
Less accumulated depreciation		281,503			254,490
Net property, plant and equipment		281,921			250,603
Net non-current assets of Therics held for sale		—			10,406
Venture capital investments		—			93,765
Other assets and deferred charges		79,371			66,316
Goodwill and other intangibles		139,649			132,282
Total assets	$	809,546		$	837,962
Liabilities and Shareholders' Equity
Current liabilities:
Accounts payable	$	47,939		$	35,861
Accrued expenses		46,651			42,409
Current portion of long-term debt		68,750			55,000
Total current liabilities		163,340			133,270
Long-term debt		148,325			204,280
Deferred income taxes		54,266			27,443
Other noncurrent liabilities		10,442			10,037
Total liabilities		376,373			375,030
Shareholders' equity:
Common stock, no par value		104,615			108,389
Common stock held in trust for savings
restoration plan		(1,212	)		(1,212	)
Unrealized gain on available-for-sale securities		3,778			586
Foreign currency translation adjustment		5,593			(4,422	)
Unrealized gain (loss) on derivative financial instruments		205			(842	)
Minimum pension liability		(3,310	)		(3,310	)
Retained earnings		323,504			363,743
Total shareholders' equity		433,173			462,932
Total liabilities and shareholders' equity	$	809,546		$	837,962

See accompanying notes to financial statements.

2

Tredegar Corporation
Consolidated Statements of Income
(In Thousands, except per share amounts)
(Unaudited)

	Third Quarter Ended Sept. 30					Nine Months Ended Sept. 30
	2003		2002			2003			2002
Revenues:
Sales	$	193,125	$	194,621		$	556,744		$	572,627
Other income (expense), net		2,379		204			3,530			620
		195,504		194,825			560,274			573,247
Costs and expenses:
Cost of goods sold		157,426		152,328			456,763			443,696
Freight		4,901		4,315			13,621			12,109
Selling, general and administrative		13,646		12,025			38,847			37,006
Research and development		4,303		5,034			14,682			15,708
Amortization of intangibles		67		11			201			89
Interest expense		1,213		2,401			4,999			6,899
Plant shutdowns, asset impairments and restructurings		3,973		178			9,940			1,442
Unusual items		—		—			1,067			—
		185,529		176,292			540,120			516,949
Income before income taxes		9,975		18,533			20,154			56,298
Income taxes		3,556		6,594			7,195			20,029
Income from continuing operations		6,419		11,939			12,959			36,269
Discontinued operations:
Loss from venture capital investment activities (including
an after-tax loss on the sale of the venture capital
investment portfolio of $49,216 in 2003)		—		(12,725	)		(49,516	)		(32,054	)
Income (loss) from operations of Molecumetics (including
an after-tax gain on the sale of intellectual property
of $891 in 2003 and loss on disposal
of $4,875 in 2002)		—		(975	)		891			(8,728	)
Income (loss) from discontinued operations		—		(13,700	)		(48,625	)		(40,782	)
Net income (loss)	$	6,419	$	(1,761	)	$	(35,666	)	$	(4,513	)
Earnings (loss) per share:
Basic:
Continuing operations	$	.17	$	.31		$	.34		$	.95
Discontinued operations		—		(.36	)		(1.28	)		(1.07	)
Net income (loss)	$	.17	$	(.05	)	$	(.94	)	$	(.12	)
Diluted:
Continuing operations	$	.17	$	.30		$	.34		$	.93
Discontinued operations		—		(.35	)		(1.26	)		(1.05	)
Net income (loss)	$	.17	$	(.05	)	$	(.92	)	$	(.12	)
Shares used to compute earnings (loss) per share:
Basic		38,058		38,334			38,094			38,258
Diluted		38,383		38,927			38,459			38,935
Dividends per share	$	.04	$	.04		$	.12		$	.12

See accompanying notes to financial statements.

3

Tredegar Corporation
Consolidated Statements of Cash Flows
(In Thousands)
(Unaudited)

	Nine Months Ended Sept. 30
	2003			2002
Cash flows from operating activities:
Net income (loss)	$	(35,666	)	$	(4,513	)
Adjustments for noncash items:
Depreciation		23,818			23,937
Amortization of intangibles		201			89
Deferred income taxes		31,257			1,092
Accrued pension income and postretirement benefits		(3,996	)		(7,179	)
Loss on venture capital investments		70,256			45,998
Gain on sale of corporate assets		(2,231	)		—
Loss on asset impairments and divestitures		2,968			7,500
Changes in assets and liabilities:
Accounts and notes receivable		(2,674	)		(16,847	)
Inventories		1,202			5,617
Income taxes recoverable		(41,895	)		1,232
Prepaid expenses and other		(1,423	)		(679	)
Accounts payable		10,323			(3,645	)
Accrued expenses		4,930			(5,764	)
Other, net		376			(1,044	)
Net cash provided by operating activities		57,446			45,794
Cash flows from investing activities:
Capital expenditures		(44,190	)		(21,564	)
Venture capital investments		(2,807	)		(14,579	)
Proceeds from the sale of venture capital investments		21,504			6,689
Proceeds from property disposals		2,385			143
Other, net		1,600			(1,696	)
Net cash used in investing activities		(21,508	)		(31,007	)
Cash flows from financing activities:
Dividends paid		(4,573	)		(4,600	)
Net decrease in borrowings		(42,205	)		(5,333	)
Repurchases of Tredegar common stock		(5,170	)		—
Proceeds from exercise of stock options		932			1,951
Net cash used in financing activities		(51,016	)		(7,982	)
(Decrease) increase in cash and cash equivalents		(15,078	)		6,805
Cash and cash equivalents at beginning of period		109,928			96,810
Cash and cash equivalents at end of period	$	94,850		$	103,615

See accompanying notes to financial statements.

4

TREDEGAR CORPORATION
NOTES TO THE CONSOLIDATED INTERIM FINANCIAL STATEMENTS
(Unaudited)

1. In the opinion of management, the accompanying consolidated financial statements of Tredegar Corporation and Subsidiaries (“Tredegar”) contain all adjustments necessary to present fairly, in all material respects, Tredegar’s consolidated financial position as of September 30, 2003, the consolidated results of operations for the three and nine months ended September 30, 2003 and 2002, and the consolidated cash flows for the nine months ended September 30, 2003 and 2002. All such adjustments are deemed to be of a normal, recurring nature. These financial statements should be read in conjunction with the consolidated financial statements and related notes included in Tredegar’s Annual Report on Form 10-K for the year ended December 31, 2002. The results of operations for the nine months ended September 30, 2003, are not necessarily indicative of the results to be expected for the full year.

2. During the second quarter of 2003 Tredegar began reporting losses associated with plant shutdowns, asset impairments and restructurings as a separate line in the Consolidated Statements of Income and Operating Profit by Segment table. These amounts were previously classified as unusual items. Prior periods have been reclassified to conform to the new presentation.

        Losses associated with plant shutdowns, asset impairments and restructurings in the third quarter of 2003 include:

• Charges for severance costs in connection with restructurings in Film Products ($321,000) and Aluminum Extrusions ($256,000);

• A pretax charge of $945,000 for asset impairments in Film Products;

• A pretax charge of $2.2 million related to the estimated loss on the expected sublease of a portion of the Therics facility in Princeton, New Jersey; and

• A pretax charge of $300,000 for additional costs incurred related to previously announced plant shutdowns in Film Products.

        Losses associated with plant shutdowns, asset impairments and restructurings in the third quarter of 2002 of $178,000 relate to the shutdown of the films plant in Carbondale, Pennsylvania.

        Losses associated with plant shutdowns, asset impairments and restructurings in the first nine months of 2003 include:

• Pretax charges for severance costs in connection with restructurings in Film Products ($1.9 million), Aluminum Extrusions ($256,000), Therics ($1.2 million) and at corporate headquarters ($1.2 million; included in “Corporate expenses, net” in the Operating Profit by Segment tables on pages 10 and 16);

• Pretax charges of $1.9 million for asset impairments in Film Products;

• A pretax charge of $388,000 related to an early retirement program in Aluminum Extrusions;

5

• Pretax charges of $2.7 million related to the estimated loss on the expected sublease of a portion of the Therics facility in Princeton, New Jersey; and

• Pretax charges of $437,000 for additional costs incurred related to previously announced plant shutdowns in Film Products.

        Losses associated with plant shutdowns, asset impairments and restructurings in the first nine months of 2002 include:

• Pretax charges of $991,000 related to the shutdown of the films plant in Carbondale, Pennsylvania;

• Pretax charges of $282,000 related to the shutdown of the films plant in Tacoma, Washington; and

• Pretax charges of $169,000 for the shutdown of the aluminum extrusions plant in El Campo, Texas.

        Unusual items in the first nine months of 2003 include a first-quarter pretax charge of $1.1 million related to an adjustment for depreciation at Therics based on Tredegar’s decision to suspend divestiture efforts. There were no unusual items during the first nine months of 2002.

        On March 7, 2003, Tredegar Investments, Inc. (“Tredegar Investments”) reached definitive agreements to sell substantially all of its portfolio of private equity partnership interests to GS Vintage Funds II, which are investment partnerships managed by Goldman Sachs Asset Management’s Private Equity Group. On the same date and in a separate transaction, Tredegar Investments also agreed to sell to W Capital Partners, an independent private equity manager, the subsidiary funds that hold substantially all of Tredegar Investments’ direct venture capital investments. The sale of these fund interests included the assumption by the buyer of Tredegar Investments’ obligations to make additional capital contributions to those funds in the future.

        The sale to W Capital Partners of the subsidiary funds that hold the direct investments occurred on March 7, 2003. The sale of the private equity fund interests occurred in a series of closings.

        Net proceeds from the sales totaled $21.5 million. An additional $54.4 million of proceeds, in the form of income tax recoveries, are expected in mid-2004 from the carry-back of 2003 capital losses generated by these sales against gains realized in 2000 by Tredegar Investments.

        The agreements governing these transactions contain customary contingent indemnification provisions that Tredegar believes will not have a material effect on its financial position or results of operations.

        The operating results from venture capital investment activities have been reported as discontinued operations and results for prior periods have been restated. Cash flows from venture capital investment activities have not been separately disclosed in the accompanying Consolidated Statements of Cash Flows. Discontinued operations for the nine months ended September 30, 2003, also include an after-tax loss on the sale of $49.2 million.

6

        On March 22, 2002, Tredegar announced its intent to divest its biotech operations. Operations were ceased at Molecumetics, Ltd. (“Molecumetics”) on July 2, 2002. The operating results of Molecumetics have been reported as discontinued operations.

        Discontinued operations are shown net of income taxes. Income taxes related to discontinued venture capital investment activities include income tax benefits of $7.2 million, $21.3 million and $18 million for the third quarter ended September 30, 2002 and the nine months ended September 30, 2003 and 2002, respectively. Income taxes related to discontinued operations of Molecumetics include income tax expense of $502,000 for the nine months ended September 30, 2003, and income tax benefits of $525,000 and $4.7 million for the third quarter and nine months ended September 30, 2002, respectively.

        During the first quarter of 2003, we suspended efforts to sell Therics, Inc. (“Therics”). Accordingly, the long-lived assets of Therics are no longer classified as held for sale and an adjustment of $1.1 million to catch up depreciation was recorded during the first quarter as an unusual item. On October 21, 2003, Tredegar announced the completion of a strategic assessment of Therics, which resulted in a decision to support the 2004 rollout of a new line of orthopaedic products. See pages 17 and 18 for more information.

3. The components of other comprehensive income or loss are as follows:

	Three Months Ended Sept. 30					Nine Months Ended Sept. 30
(In Thousands)	2003		2002			2003			2002
Net income (loss)	$	6,419	$	(1,761	)	$	(35,666	)	$	(4,513	)
Other comprehensive income (loss):
Available-for-sale securities adjustment, net
of reclassification adjustment		2,709		(1,798	)		3,192			(7,752	)
Foreign currency translation adjustment		862		(2,708	)		10,015			(1,988	)
Derivative financial instrument adjustment		63		(266	)		1,047			874
Minimum pension liability adjustment		—		—			—			—
Comprehensive income (loss)	$	10,053	$	(6,533	)	$	(21,412	)	$	(13,379	)

4. The components of inventories are as follows:

(In Thousands)	Sept. 30, 2003		Dec. 31, 2002
Finished goods	$	8,193	$	7,841
Work-in-process		3,940		3,905
Raw materials		21,495		21,076
Stores, supplies and other		10,744		11,147
Total	$	44,372	$	43,969

7

5. Basic earnings per share is computed by dividing net income by the weighted average number of shares of common stock outstanding. Diluted earnings per share is computed by dividing net income by the weighted average common and potentially dilutive common equivalent shares outstanding, determined as follows:

	Three Months Ended Sept. 30				Nine Months Ended Sept. 30
(In Thousands)	2003		2002		2003		2002
Weighted average shares outstanding used
to compute basic earnings per share		38,058		38,334		38,094		38,258
Incremental shares issuable upon the
assumed exercise of stock options		325		593		365		677
Shares used to compute diluted earnings
per share		38,383		38,927		38,459		38,935

        Incremental shares issuable upon the assumed exercise of outstanding stock options are computed using the average market price during the related period. During 2003 and 2002, options to purchase 2,252,105 and 2,131,175 shares, respectively, were excluded from the calculation of incremental shares issuable upon the assumed exercise of stock options due to their anti-dilutive effect on earnings per share for the period.

6. Pursuant to our stock option plans, options to purchase 594,500 shares were granted during the first quarter of 2002. None were granted during the second quarter of 2002 and options to purchase 10,000 shares were granted during the third quarter of 2002. During 2003, no stock options were granted during the first and second quarters and options to purchase 10,000 shares were granted during the third quarter.

        We account for stock options granted to employees and directors in accordance with Accounting Principles Board Opinion No. 25, “Accounting for Stock Issued to Employees.”Accordingly, no compensation expense has been recognized since the exercise price of the options was equal to the fair value of the underlying common stock on the date of grant. Had compensation cost for our stock-based compensation plans been determined based on the fair value of the options at the grant dates consistent with the method of accounting under Statement of Financial Accounting Standards No. 123, “Accounting for Stock Based Compensation,” our income and diluted earnings per share from continuing operations would have been reduced to the pro forma amounts indicated below:

	Three Months Ended Sept. 30						Nine Months Ended Sept. 30
(In Thousands, except per share data)	2003			2002			2003			2002
Income from continuing operations:
As reported	$	6,419		$	11,939		$	12,959		$	36,269
Stock-based compensation cost, net of tax,
based on the fair value method		(556	)		(567	)		(1,646	)		(1,701	)
Pro forma income from continuing operations	$	5,863		$	11,372		$	11,313		$	34,568
Diluted earnings per share from continuing operations:
As reported		.17			.30			.34			.93
Pro forma		.15			.29			.29			.89

8

        For the purposes of the above presentation, the fair value of each option was estimated as of the grant date using the Black-Scholes option-pricing model. The weighted-average assumptions used in this model are provided for 2002 below (similar assumptions were used for the stock option grant of 10,000 shares during the third quarter of 2003):

2002
Dividend yield	.9	%	Weighted average market price at
Volatility percentage	45.0	%	date of grant:
Weighted average risk-free			Officers and management	$	18.71
interest rate	4.7	%	Other employees		18.90
Holding period (years):			Estimated weighted average fair value
Officers	7.0		of options per share at date of grant:
Management	5.0		Officers		9.14
Other employees	3.0		Management		8.02
			Other employees		6.20

7. At September 30, 2003, Tredegar Investments held 660,642 shares of Vascular Solutions, Inc. (NASDAQ: VASC) and 813,455 shares of Illumina, Inc. (NASDAQ: ILMN). These securities relate to Tredegar Investments’ earlier venture capital investment activities and are classified as available-for-sale securities. These holdings, which are included in the Consolidated Balance Sheets in “Other assets and deferred charges” at September 30, 2003 ($8.2 million market value), and “Venture capital investments” at December 31, 2002 ($3.6 million market value), are stated at market value with unrealized gains reported directly in shareholders’ equity net of related deferred income taxes.

        Gains on the sale of corporate assets in the third quarter and first nine months of 2003 include pretax gains of $942,000 on the sale of public securities and $1.3 million on the sale of corporate real estate (included in “Other income (expense), net” in the Consolidated Statements of Income).

8. On October 17, 2003, we refinanced our debt with a new $250 million credit agreement (the “Credit Agreement”) consisting of a $175 million three-year revolving credit facility and a $75 million three-year term loan. The amount available under the revolving credit facility is reduced by $50 million on the earlier of the receipt of the $54.4 million income tax recoveries related to the sale of the venture capital portfolio (see Note 2) or September 15, 2004. See pages 19 – 22 for more information.

9

9. Information by business segment is reported below. There are no accounting transactions between segments and no allocations to segments. There have been no significant changes to identifiable assets by segment other than for Tredegar Investments due to the sale of substantially all of our venture capital investment portfolio (see Note 2). Net sales (sales less freight) and operating profit from ongoing operations are the measures of sales and operating profit used by the chief operating decision maker of each segment for purposes of assessing performance. See Note 2 regarding the reclassification of unusual items and losses associated with plant shutdowns, asset impairments and restructurings.

Tredegar Corporation
Net Sales and Operating Profit by Segment
(In Thousands)
(Unaudited)

	Third Quarter Ended Sept. 30						Nine Months Ended Sept. 30
	2003			2002			2003			2002
Net Sales
Film Products	$	92,188		$	94,473		$	273,982		$	280,667
Aluminum Extrusions		96,036			95,813			269,141			279,643
Therics		—			20			—			208
Total net sales		188,224			190,306			543,123			560,518
Add back freight		4,901			4,315			13,621			12,109
Sales as shown in the Consolidated Statements of Income	$	193,125		$	194,621		$	556,744		$	572,627
Operating Profit
Film Products:
Ongoing operations	$	10,807		$	16,645		$	34,839		$	53,442
Plant shutdowns, asset impairments and restructurings		(1,566	)		(178	)		(4,260	)		(1,273	)
		9,241			16,467			30,579			52,169
Aluminum Extrusions:
Ongoing operations		6,542			8,107			12,608			23,737
Plant shutdowns, asset impairments and restructurings		(256	)		—			(644	)		(169	)
		6,286			8,107			11,964			23,568
Therics:
Ongoing operations		(2,618	)		(3,263	)		(9,221	)		(10,090	)
Restructurings		(2,151	)		—			(3,855	)		—
Unusual items		—			—			(1,067	)		—
		(4,769	)		(3,263	)		(14,143	)		(10,090	)
Total operating profit		10,758			21,311			28,400			65,647
Interest income		253			448			1,086			1,498
Interest expense		1,213			2,401			4,999			6,899
Gain on the sale of corporate assets		2,231			—			2,231			—
Corporate expenses, net		2,054			825			6,564			3,948
Income before income taxes		9,975			18,533			20,154			56,298
Income taxes		3,556			6,594			7,195			20,029
Income from continuing operations		6,419			11,939			12,959			36,269
Income (loss) from discontinued operations		—			(13,700	)		(48,625	)		(40,782	)
Net income (loss)	$	6,419		$	(1,761	)	$	(35,666	)	$	(4,513	)

10

Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations.

Critical Accounting Policies

        In the ordinary course of business, we make a number of estimates and assumptions relating to the reporting of results of operations and financial position in the preparation of financial statements in conformity with generally accepted accounting principles. We believe the estimates, assumptions and judgments described in the section “Management’s Discussion and Analysis of Financial Condition and Results of Operations – Critical Accounting Policies” of our Annual Report on Form 10-K for the year ended December 31, 2002, have the greatest potential impact on our financial statements, so we consider these to be our critical accounting policies. These policies include our accounting for impairment of long-lived assets and goodwill, investments, deferred tax assets and pension benefits. These policies require management to exercise judgments that are often difficult, subjective and complex due to the necessity of estimating the effect of matters that are inherently uncertain. Actual results could differ significantly from those estimates under different assumptions and conditions. We believe the consistent application of these policies enables us to provide readers of our financial statements with useful and reliable information about our operating results and financial condition. There has been no significant change in these policies, or the estimates used in the application of these policies since our 2002 fiscal year-end.

Results of Operations

Third Quarter 2003 Compared with Third Quarter 2002

        Net income from continuing operations was $6.4 million (17 cents per share) in the third quarter of 2003 compared with $11.9 million (30 cents per share) in 2002.

        Discontinued operations in 2002 include an after-tax loss of $12.7 million related to venture capital investment activities and an after-tax loss of $975,000 related to Molecumetics. There were no discontinued operations in the third quarter of 2003. See Note 2 on page 5 for more information on discontinued operations.

        Overall, sales in 2003 decreased less than 1% compared with 2002. Net sales (sales less freight) and volume declined in Film Products and increased in Aluminum Extrusions. For more information on net sales and volume, see the business segment review beginning on page 16.

        Gross profit (sales minus cost of goods sold and freight) as a percentage of sales decreased to 15.9% in 2003 from 19.5% in 2002. At Film Products, an overall lower gross profit margin was driven primarily by the loss of certain domestic backsheet business (lower overall contribution to cover fixed costs), higher raw material prices and higher manufacturing costs on certain new products. At Aluminum Extrusions, the gross profit margin declined primarily due to higher energy costs, higher insurance costs and the impact of the Canadian Dollar appreciating against the U.S. Dollar.

        As a percentage of sales, selling, general and administrative (“SG&A”) expenses increased to 7.1% compared with 6.2% in 2002, primarily due to appreciation of the Canadian Dollar and Euro against the U.S. Dollar, higher employee-related costs and expenses associated with commencing the implementation of a new information system in Film Products.

11

        Research and development (“R&D”) expenses declined to $4.3 million in the third quarter of 2003 from $5 million in 2002. R&D spending at Therics declined to $2.5 million in 2003 from $3.1 million in 2002 due to cost reduction efforts. R&D spending at Film Products was $1.8 million in 2003, down $100,000 from last year.

        Gains on the sale of corporate assets in the third quarter of 2003 include pretax gains of $942,000 on the sale of public securities and $1.3 million on the sale of corporate real estate (included in “Other income (expense), net” in the Consolidated Statements of Income).

        Losses associated with plant shutdowns, asset impairments and restructurings in the third quarter of 2003 include:

• Charges for severance costs in connection with restructurings in Film Products ($321,000) and Aluminum Extrusions ($256,000);

• A pretax charge of $945,000 for asset impairments in Film Products;

• A pretax charge of $2.2 million related to the estimated loss on the expected sublease of a portion of the Therics facility in Princeton, New Jersey; and

• A pretax charge of $300,000 for additional costs incurred related to previously announced plant shutdowns in Film Products.

        Losses associated with plant shutdowns, asset impairments and restructurings in the third quarter of 2002 of $178,000 relate to the shutdown of the films plant in Carbondale, Pennsylvania.

        For more information on costs and expenses, see the business segment review beginning on page 16.

        Interest income, which is included in “Other income (expense), net” in the Consolidated Statements of Income, was $253,000 in 2003 and $448,000 in 2002. Interest income was down primarily due to a lower average tax equivalent yield earned on cash equivalents (about 1% in 2003 and 1.8% in 2002). Our policy permits investment of excess cash in marketable securities that have the highest credit ratings and maturities of less than one year. The primary objectives of our policy are safety of principal and liquidity.

12

        Interest expense was $1.2 million in 2003 compared with $2.4 million in 2002. Average debt outstanding and interest rates were as follows:

	Three Months Ended Sept. 30
(In Millions)	2003			2002
Floating-rate debt with interest charged on a
rollover basis at one-month LIBOR:
Average outstanding debt balance	$	214.4		$	175.0
Average interest rate		1.8	%		2.5	%
Floating-rate debt fixed via interest rate swaps in the
second quarter of 2001 and maturing in the second
quarter of 2003:
Average outstanding debt balance	$	—		$	75.0
Average interest rate		—			5.4	%
Fixed-rate and other debt:
Average outstanding debt balance	$	4.6		$	9.3
Average interest rate		7.5	%		7.2	%
Total debt:
Average outstanding debt balance	$	219.0		$	259.3
Average interest rate		1.9	%		3.4	%

        The effective tax rate from continuing operations was 35.6% in the third quarters of 2003 and 2002.

Nine Months 2003 Compared with Nine Months 2002

        The net loss for the first nine months of 2003 was $35.7 million (92 cents per share) compared with a net loss of $4.5 million (12 cents per share) in 2002. Net income from continuing operations was $13 million (34 cents per share) in 2003 compared with $36.3 million (93 cents per share) in 2002.

        Discontinued operations for the first nine months of 2003 include a loss of $49.5 million related to venture capital investment activities (including an after-tax loss on the sale of the venture capital investment portfolio of $49.2 million) and an after-tax gain of $891,000 on the sale of intellectual property related to Molecumetics. Discontinued operations in 2002 include an after-tax loss of $32.1 million related to venture capital investment activities and an after-tax loss of $8.7 million related to Molecumetics. See Note 2 on page 5 for more information on discontinued operations.

        Overall, sales for the first nine months of 2003 decreased 2.8% compared with 2002. Net sales (sales less freight) for Film Products and Aluminum Extrusions declined primarily due to lower sales volume. For more information on net sales, see the business segment review beginning on page 16.

        Gross profit (sales less cost of goods sold and freight) as a percentage of sales decreased to 15.5% in the first nine months of 2003 from 20.4% in 2002. This decrease is primarily attributable to the reasons that resulted in the third quarter decline as described on page 11.

13

        As a percentage of sales, SG&A expenses increased to 7.0% compared with 6.5% in 2002, primarily due to lower sales, the appreciation of the Canadian Dollar and Euro against the U.S. Dollar, higher employee-related costs and expenses associated with commencing the implementation of a new information system in Film Products.

        R&D expenses for the first nine months declined to $14.7 million in 2003 ($8.8 million for Therics and $5.9 million for Film Products) from $15.7 million in 2002 ($9.7 million for Therics and $6.0 million for Film Products). The decline was primarily due to cost reduction efforts at Therics.

        Gains on the sale of corporate assets in 2003 include pretax gains of $942,000 on the sale of public securities and $1.3 million on the sale of corporate real estate (included in “Other income (expense), net” in the Consolidated Statements of Income).

        Losses associated with plant shutdowns, asset impairments and restructurings in the first nine months of 2003 include:

• Pretax charges for severance costs in connection with restructurings in Film Products ($1.9 million),  Aluminum Extrusions ($256,000), Therics ($1.2 million) and at corporate headquarters ($1.2 million; included in “Corporate expenses, net” in the Operating Profit by Segment tables on pages 10 and 16);

• Pretax charges of $1.9 million for asset impairments in Film Products;

• A pretax charge of $388,000 related to an early retirement program in Aluminum Extrusions;

• Pretax charges of $2.7 million related to the estimated loss on the expected sublease of a portion of the Therics facility in Princeton, New Jersey; and

• Pretax charges of $437,000 for additional costs incurred related to previously announced plant shutdowns in Film Products.

        Losses associated with plant shutdowns, asset impairments and restructurings in the first nine months of 2002 include:

• Pretax charges of $991,000 related to the shutdown of the films plant in Carbondale, Pennsylvania;

• Pretax charges of $282,000 related to the shutdown of the films plant in Tacoma, Washington; and

• Pretax charges of $169,000 for the shutdown of the aluminum extrusions plant in El Campo, Texas.

        Unusual items in the first nine months of 2003 include a first-quarter pretax charge of $1.1 million related to an adjustment for depreciation at Therics based on Tredegar’s decision to suspend divestiture efforts. There were no unusual items during the first nine months of 2002.

        For more information on costs and expenses, see the business segment review beginning on page 16.

        Interest income, which is included in “Other income (expense), net” in the Consolidated Statements of Income, was $1.1 million in the first nine months of 2003 and $1.5 million in 2002. Despite a higher average cash and cash equivalents balance, interest income was down due to lower average tax equivalent yield earned on cash equivalents (1.1% in 2003 and 2% in 2002).

14

        Interest expense for the first nine months was $5 million in the 2003 compared with $6.9 million in 2002. Average debt outstanding and interest rates for the first nine months of 2003 and 2002 were as follows:

	Nine Months Ended Sept. 30
(In Millions)	2003			2002
Floating-rate debt with interest charged on a
rollover basis at one-month LIBOR:
Average outstanding debt balance	$	188.3		$	175.0
Average interest rate		1.9	%		2.5	%
Floating-rate debt fixed via interest rate swaps in the
second quarter of 2001 and maturing in the second
quarter of 2003:
Average outstanding debt balance	$	38.5		$	75.0
Average interest rate		5.4	%		5.4	%
Fixed-rate and other debt:
Average outstanding debt balance	$	7.6		$	12.5
Average interest rate		7.3	%		7.2	%
Total debt:
Average outstanding debt balance	$	234.4		$	262.5
Average interest rate		2.7	%		3.5	%

        The effective tax rate from continuing operations was 35.7% in the first nine months of 2003 and 35.6% in 2002.

15

Business Segment Review

        The following tables present Tredegar’s net sales and operating profit by segment for the third quarters and nine months ended September 30, 2003 and 2002:

Tredegar Corporation
Net Sales and Operating Profit by Segment
(In Thousands)
(Unaudited)

	Third Quarter Ended Sept. 30						Nine Months Ended Sept. 30
	2003			2002			2003			2002
Net Sales
Film Products	$	92,188		$	94,473		$	273,982		$	280,667
Aluminum Extrusions		96,036			95,813			269,141			279,643
Therics		—			20			—			208
Total net sales		188,224			190,306			543,123			560,518
Add back freight		4,901			4,315			13,621			12,109
Sales as shown in the Consolidated Statements of Income	$	193,125		$	194,621		$	556,744		$	572,627
Operating Profit
Film Products:
Ongoing operations	$	10,807		$	16,645		$	34,839		$	53,442
Plant shutdowns, asset impairments and restructurings		(1,566	)		(178	)		(4,260	)		(1,273	)
		9,241			16,467			30,579			52,169
Aluminum Extrusions:
Ongoing operations		6,542			8,107			12,608			23,737
Plant shutdowns, asset impairments and restructurings		(256	)		—			(644	)		(169	)
		6,286			8,107			11,964			23,568
Therics:
Ongoing operations		(2,618	)		(3,263	)		(9,221	)		(10,090	)
Restructurings		(2,151	)		—			(3,855	)		—
Unusual items		—			—			(1,067	)		—
		(4,769	)		(3,263	)		(14,143	)		(10,090	)
Total operating profit		10,758			21,311			28,400			65,647
Interest income		253			448			1,086			1,498
Interest expense		1,213			2,401			4,999			6,899
Gain on the sale of corporate assets		2,231			—			2,231			—
Corporate expenses, net		2,054			825			6,564			3,948
Income before income taxes		9,975			18,533			20,154			56,298
Income taxes		3,556			6,594			7,195			20,029
Income from continuing operations		6,419			11,939			12,959			36,269
Income (loss) from discontinued operations		—			(13,700	)		(48,625	)		(40,782	)
Net income (loss)	$	6,419		$	(1,761	)	$	(35,666	)	$	(4,513	)

16

        Net sales (sales less freight) and operating profit from ongoing operations are the measures of sales and operating profit used by the chief operating decision maker of each segment for purposes of assessing performance. See Note 2 on page 5 regarding the reclassification of unusual items and losses associated with plant shutdowns, asset impairments and restructurings.

        Net sales and operating profit from ongoing operations in Film Products were down 2.4% and 35%, respectively, in the third quarter, and 2.4% and 35%, respectively, for the first nine months. Volume for the quarter was 68 million pounds, down 8% from 74 million pounds in 2002. Year-to-date volume decreased 11% to 207 million pounds from 232 million pounds. Net sales, operating profit and volume in the second quarter of 2003, the first full quarter reflecting the loss of certain discontinued domestic backsheet business with The Procter & Gamble Company (“P&G”), were $88.4 million, $10.1 million and 66 million pounds, respectively. On a sequential basis (third quarter 2003 compared to second quarter of 2003) net sales, operating profit and volume were up 4.2%, 7% and 3.3%, respectively.

        Film Products’ strategy is based on expanding sales of apertured, elastic and specialty products. Sales of these and other products that are unrelated to certain discontinued domestic backsheet business continue to grow and now comprise approximately 90% of Film Products’ revenue. Expectations for near-term profit improvement are tempered by higher costs related to recent resin price increases, new product introductions and capacity additions in Europe, China and the U.S. Cost reduction activities are continuing, including the qualification of new lower cost resins, manufacturing efficiency efforts and the closure of the plant in New Bern, North Carolina. Operating profit from ongoing operations is expected to remain near third-quarter levels in the fourth quarter and gradually improve in 2004.

        Third-quarter net sales in Aluminum Extrusions were flat at $96 million while operating profit from ongoing operations declined to $6.5 million, down 20% from $8.1 million in 2002. Volume was 63 million pounds for the quarter, up 1% from 62 million pounds in 2002. Profits continue to be affected by higher energy and insurance costs. Appreciation of the Canadian Dollar against the U.S. Dollar also had an adverse impact (see “Quantitative and Qualitative Disclosures About Market Risk” on page 22). On a sequential basis, net sales were up 8% while operating profit improved by $1.6 million or 35% over second-quarter results. Volume was up 9% compared to the second quarter.

        Year-to-date net sales were $269.1 million, down 4% from $279.6 million in 2002. Operating profit from ongoing operations for the nine-month period was $12.6 million, down 47% from $23.7 million in 2002. Year-to-date volume decreased 4% to 174 million pounds, down from 181 million pounds in 2002. Lower year-to-date operating profits are due primarily to the decline in volume and the other factors noted above in describing third quarter results.

        Customer orders in Aluminum Extrusions have declined to levels similar to 2002 after showing improvement early in the third quarter, and the business is now entering the seasonally weak winter months. Given these factors, fourth-quarter aluminum profits are not likely to show improvement over year-ago levels.

        The third-quarter operating loss from ongoing operations at Therics was $2.6 million compared to a loss of $3.3 million in 2002. On a similar basis, the year-to-date loss was $9.2 million compared to $10.1 million in 2002. On October 21, 2003, we announced the completion of a strategic assessment of Therics, which resulted in a decision to support the 2004 rollout of a new line of orthopaedic products. This decision is based on our belief that Therics’ technology has value. It also reflects our confidence in the new management team at Therics, which is highly focused on bringing the first product line to market and controlling expenses. Therics’ management expects the company to begin generating revenue in the first half of 2004. We will monitor Therics’ near-term progress against milestones that are clearly defined and measurable.

17

        Therics has developed an initial family of products that is expected to be launched in the first half of 2004. These products will be introduced into the orthobiologics sector of orthopaedic and neurosurgical medicine, specifically the growing market for bone graft substitutes. Orthobiologic products use biology and biochemistry to repair, replace or regenerate musculoskeletal structures.

        We expect near-term operating losses at Therics to remain around $3 million per quarter. Operating losses should decline assuming sales begin to ramp up in the second half of 2004.

Liquidity and Capital Resources

        Tredegar’s total assets decreased to $809.5 million at September 30, 2003, from $838 million at December 31, 2002, due primarily to the impact of the sale of substantially all of the venture capital investment portfolio, partially offset by capital expenditures in excess of depreciation, positive foreign currency translation adjustments associated with Canadian and European operations and appreciation of $4.6 million of shares held in Vascular Solutions, Inc. (NASDAQ: VASC) and Illumina, Inc. (NASDAQ: ILMN).

        The net deferred income tax liability (deferred income tax liabilities minus deferred income tax assets) increased to $45.5 million at September 30, 2003, from $6.5 million at December 31, 2002, due to the reversal of deferred tax assets totaling approximately $35 million related to the sale of the venture capital portfolio. Pretax proceeds from the sale totaled $21.5 million. An additional $54.4 million of proceeds, in the form of income tax recoveries, are expected in mid-2004 from the carry-back of 2003 capital losses generated by these sales against gains realized in 2000 by Tredegar Investments. See Note 2 on page 5 for more information.

        Cash provided by operating activities was $57.4 million in the first nine months of 2003 compared with $45.8 million in 2002. The increase is due primarily to a decrease in the level of primary working capital (accounts receivable, inventories and accounts payable).

        Cash used in investing activities was $21.5 million in the first nine months of 2003 compared with cash used in investing activities of $31 million in 2002. The change is primarily attributable to proceeds from the sale of venture capital investments, net of investments made, of $18.7 million in 2003 versus a net investment of $7.9 million in 2002. This was partially offset by higher capital expenditures, an increase of $22.6 million.

18

        Capital expenditures in the first nine months of 2003 reflect the normal replacement of machinery and equipment and:

• Machinery and equipment purchased to upgrade lines and expand capacity at our films plant in Kerkrade, The Netherlands;

• Expansion of capacity at our films plant in Shanghai, China;

• Construction of a new films plant in Guangzhou, China;

• Commencing the implementation of a new information system in Film Products; and

• Machinery and equipment purchased to upgrade our wastewater treatment system at our aluminum extrusions plant in Newnan, Georgia.

        Cash used in financing activities was $51 million in the first nine months of 2003 versus $8 million in 2002. This change is attributable to repayments of debt in the total amount of $42.2 million in 2003. In addition, we repurchased 406,400 shares of our common stock during the first six months of 2003 for a total of $5.2 million (an average price of $12.72 per share). There were no purchases during the third quarter of 2003.

        Debt outstanding of $217.1 million at September 30, 2003, consisted of a $212.5 million term loan and other debt of $4.6 million. On October 17, 2003, we refinanced our debt with a new $250 million credit agreement consisting of a $175 million three-year revolving credit facility and a $75 million three-year term loan. The amount available under the revolving credit facility is reduced by $50 million on the earlier of the receipt of the $54.4 million income tax recoveries related to the sale of the venture capital portfolio (see Note 2 on page 5) or September 15, 2004. Term loan installments are due as follows:

Term Loan Quarterly Repayment Schedule (In Thousands)
Installment due each quarter on December 31, 2003, and March 31, June
30 and September 30, 2004	$	1,875
Installment due each quarter on December 31, 2004, and March 31, June
30 and September 30, 2005		3,125
Installment due each quarter on December 31, 2005, and March 31 and
June 30, 2006		3,750
Final payment due on September 30, 2006		43,750

19

        Pro forma capitalization as if the Credit Agreement were in place as of September 30, 2003, is provided below:

Pro Forma Capitalization as of September 30, 2003 (In Thousands)
	As Reported		Debt Paydown & Refinancing			Pro Forma
Net capitalization and deferred debt
issuance costs:
Cash and cash equivalents	$	94,850	$	(63,834	)	$	31,016
Debt:
Term loan		212,500		(212,500	)		—
Credit Agreement:
Revolver		—		75,000			75,000
Term loan		—		75,000			75,000
Other debt		4,575		—			4,575
Total debt		217,075		(62,500	)		154,575
Debt net of cash and cash equivalents		122,225		1,334			123,559
Shareholders’ equity		433,173		—			433,173
Net capitalization	$	555,398	$	1,334		$	556,732
Deferred debt issuance costs	$	738	$	596		$	1,334
Indebtedness:
Total debt	$	217,075	$	(62,500	)	$	154,575
Face value of letters of credit		6,791		—			6,791
Indebtedness	$	223,866	$	(62,500	)	$	161,366

        Excluded from the pro forma analysis above are income tax recoveries of $54.4 million expected in mid-2004 related to the sale of the venture capital portfolio. See Note 2 on page 5 for more information.

        The credit spread over LIBOR and commitment fees charged on the unused amount under the Credit Agreement at various indebtedness-to-adjusted EBITDA levels are as follows:

	Credit Spread Over LIBOR Under Credit Agreement (Basis Points)
Indebtedness-to- Adjusted EBITDA Ratio	Revolver ($75 Million Outstanding at 10/31/03)		Term Loan ($75 Million Outstanding at 10/31/03)		Commitment Fee (Basis Points)
› 2x but ‹= 3x		150.0		150.0		30.0
› 1x but ‹= 2x		125.0		125.0		25.0
‹= 1x		100.0		100.0		20.0

        The computations of adjusted EBITDA, adjusted EBIT, the leverage ratio and interest coverage ratio as defined in the Credit Agreement are presented below along with the related most restrictive covenants. Adjusted EBITDA and adjusted EBIT as defined in the Credit Agreement are not intended to represent cash flow from operations as defined by GAAP and should not be considered as either an alternative to net income or to cash flow.

20

Computations of Adjusted EBITDA, Adjusted EBIT, Leverage Ratio and Interest Coverage Ratio as Defined in Credit Agreement Along with Related Most Restrictive Covenants For the Twelve Months Ended September 30, 2003 (In Thousands)
Computations of adjusted EBITDA and adjusted EBIT as defined in
Credit Agreement:
Net loss	$	(33,684	)
Plus:
After-tax losses related to discontinued operations		58,999
Total income tax expense for continuing operations		14,047
Interest expense		7,452
Depreciation and amortization expense for continuing operations		31,927
All non-cash losses and expenses, plus cash losses and expenses not
to exceed $10 million, for continuing operations that are classified as
unusual, extraordinary or which are related to plant shutdowns, asset
impairments and/or restructurings		12,920
Minus:
After-tax income related to discontinued operations		—
Total income tax benefits for continuing operations		—
Interest income		(1,522	)
All non-cash gains and income, plus cash gains and
income not to exceed $10 million, for continuing operations that are
classified as unusual, extraordinary or which are related to plant
shutdowns, asset impairments and/or restructurings		(7,849	)
Plus or minus, as applicable, pro forma EBITDA adjustments associated
with acquisitions and asset dispositions		—
Adjusted EBITDA as defined in Credit Agreement		82,290
Less: Depreciation and amortization expense for continuing
operations		(31,927	)
Adjusted EBIT as defined in Credit Agreement	$	50,363
Computations of leverage and interest coverage ratios as defined in
Credit Agreement:
Leverage ratio (pro forma indebtedness-to-adjusted EBITDA)		1.96x
Interest coverage ratio (adjusted EBIT-to-interest expense)		6.76x
Most restrictive covenants as defined in Credit Agreement:
Maximum permitted aggregate amount of dividends that can be paid
by Tredegar during the term of the Credit Agreement	$	100,000
Minimum adjusted shareholders' equity permitted (increases by
50% of net income generated after September 30, 2003)		325,000
Maximum leverage ratio permitted:
Ongoing		3.00x
Pro forma for acquisitions		2.50x
Minimum interest coverage ratio permitted		2.50x

21

        Noncompliance with any one or more of the debt covenants may have an adverse effect on financial condition or liquidity in the event such noncompliance is incapable of being cured or should we be unable to obtain a waiver from the lenders. Renegotiation of the covenant through an amendment to the Credit Agreement may effectively cure the noncompliance, but may have an effect on financial condition or liquidity depending upon how the covenant is renegotiated.

        We believe that existing borrowing availability, our current cash balances and our cash flow from operations will be sufficient to satisfy our working capital, capital expenditure and dividend requirements for the foreseeable future.

Quantitative and Qualitative Disclosures About Market Risk

        Tredegar has exposure to the volatility of interest rates, polyethylene and polypropylene resin prices, aluminum ingot and scrap prices, energy prices, foreign currencies and emerging markets.

        Changes in resin prices, and the timing of those changes, could have a significant impact on profit margins in Film Products. Profit margins in Aluminum Extrusions are sensitive to fluctuations in aluminum ingot and scrap prices as well as natural gas prices. There is no assurance of our ability to pass through higher raw material and energy costs to our customers.

        In the normal course of business, we enter into fixed-price forward sales contracts with certain customers for the sale of fixed quantities of aluminum extrusions at scheduled intervals. To hedge our exposure to aluminum price volatility under these fixed-price arrangements, which generally have a duration of not more than 12 months, we enter into a combination of forward purchase commitments and futures contracts to acquire aluminum, based on scheduled deliveries.

        In Aluminum Extrusions, we hedge from time-to-time a portion of our exposure to natural gas price volatility by entering into fixed-price forward purchase contracts with our natural gas suppliers.

        We sell to customers in foreign markets through our foreign operations and through exports from U.S. plants. The percentage of consolidated net sales from manufacturing operations related to foreign markets for the first nine months of 2003 and 2002 are presented below:

Percentage of Net Sales from Manufacturing Operations Related to Foreign Markets*
	Nine Months Ended Sept. 30
	2003						2002
	Exports From U.S.			Foreign Operations			Exports From U.S.			Foreign Operations
Canada		4	%		17	%		3	%		18	%
Europe		3			12			3			9
Latin America		3			2			3			2
Asia		3			2			4			2
Total		13	%		33	%		13	%		31	%

* Based on consolidated net sales from manufacturing operations
(excludes Therics and discontinued operations).

22

        We attempt to match the pricing and cost of our products in the same currency and generally view the volatility of foreign currencies and emerging markets, and the corresponding impact on earnings and cash flow, as part of the overall risk of operating in a global environment. Exports from the U.S. are generally denominated in U.S. Dollars. Our foreign currency exposure on income from foreign operations in Europe primarily relates to the Euro. In Canada, the U.S. Dollar-based spread (the difference between selling prices and aluminum costs) generated from Canadian casting operations and exports from Canada to the U.S. are currently in excess of our Canadian Dollar-based operating profit. Consequently, at current sales levels our Canadian aluminum extrusion operations will generally be negatively affected by appreciation of the Canadian Dollar relative to the U.S. Dollar, and positively affected by depreciation of the Canadian Dollar relative to the U.S. Dollar.

Forward-Looking and Cautionary Statements

        From time to time, we may make statements that may constitute “forward-looking statements” within the meaning of the “safe-harbor” provisions of the Private Securities Litigation Reform Act of 1995. Such statements are based on our then current expectations and are subject to a number of risks and uncertainties that could cause actual results to differ materially from those addressed in the forward-looking statements. Factors that may cause such a difference include, but are not limited to the following:

General

• Our future performance is influenced by costs incurred by our operating companies including, forexample, the cost of energy and raw materials.There is no assurance that we will be able to offset fully the effects of higher raw material costs through price increases. Further, there is no assurance that cost control efforts will positively impact results or that such efforts could be increased to a level that offsets any additional future declines in revenue or increases in energy, raw material or other costs.

Film Products

• Film Products is highly dependent on sales associated with one customer, P&G. P&G comprised 33% of Tredegar’s net sales in 2002, 31% in 2001 and 28% in 2000. The loss or significant reduction of sales associated with P&G would have a material adverse effect on our business, as would delays in P&G rolling out products utilizing new technologies developed by Tredegar. While we have undertaken efforts to expand our customer base, there can be no assurance that such efforts will be successful, or that they will offset any delay or loss of sales and profits associated with P&G. See the business segment review beginning on page 17 for a discussion regarding the loss of P&G’s domestic diaper backsheet business.

• Growth of Film Products depends on our ability to develop and deliver new products, especially in thepersonal care market, which comprised over 75% of Film Products’ net sales in each of the last three years. Personal care products are now being made with a variety of new materials, replacing traditional backsheet and other components. While we have substantial technical resources, there can be no assurance that our new products can be brought to market successfully, or if brought to market successfully, at the same level of profitability and market share of replaced films. A shift in customer preferences away from our technologies, our inability to develop and deliver new profitable products, or delayed acceptance of our new products in domestic or foreign markets, could have a material adverse effect on our business.

23

• Film Products operates in a field where our significant customers and competitors have substantialintellectual property portfolios.The continued success of this business depends on our ability not only to protect our own technologies and trade secrets, but also to develop and sell new products that do not infringe upon existing patents. Although we are not currently involved in any patent litigation, an unfavorable outcome of any such action could have a significant adverse impact on Film Products.

• As Film Products expands its personal care business, we have greater credit risk that is inherent inbroadening our customer base.

Aluminum Extrusions

• Sales volume and profitability of Aluminum Extrusions is cyclical and highly dependent on economicconditions of end-use markets in the United States and Canada, particularly in the construction,distribution and transportation industries.Our market segments are also subject to seasonal slowdowns during the winter months. From 1992 to the second quarter of 2000, profits in Aluminum Extrusions grew as a result of positive economic conditions in the markets we serve and manufacturing efficiencies. However, a slowdown in these markets in the second half of 2000 resulted in a 13% decline in sales volume and 28% decline in ongoing operating profit compared with the second half of 1999. The aluminum extrusions industry continued to be affected by poor economic conditions in 2001 and 2002. Our sales volume declined 23% and operating profit declined 49% in 2002 compared with 2000. In 2001, our sales volume declined 20% and operating profit declined 52% compared with 2000. The decline in ongoing operating profit during these periods at approximately two to three times the rate of the decline in sales volume illustrates the operating leverage inherent in our operations (fixed operating costs). Moreover, in 2003 higher energy and insurance costs and the appreciation of the Canadian Dollar against the U.S. Dollar had an adverse impact on operating profits. Any benefits associated with cost reductions and productivity improvements may not be sufficient to offset the adverse effects on profitability from pricing and margin pressure and higher bad debts that usually accompany a downturn.

• The markets for our products are highly competitive with product quality, service and price being theprincipal competitive factors. As competitors increase capacity or reduce prices to increase business, there could be pressure to reduce prices to our customers. Aluminum Extrusions is under increasing domestic and foreign competitive pressures, including a growing presence of Chinese imports in a number of markets. This competition could result in loss of market share due to a competitor’s ability to produce at lower costs and sell at lower prices. There can be no assurance that we will be able to maintain current margins and profitability. Our continued success and prospects depend on our ability to retain existing customers and participate in overall industry cross-cycle growth.

24

Therics

• Therics has incurred losses since inception, and we are unsure when, or if, it will become profitable. There can be no assurance that any new products can be brought to market successfully. In addition, there can be no assurance that the FDA and other regulatory authorities will clear our products in a timely manner.

• Therics’ prospects and value depend on its ability to develop, manufacture, market, sell and profit fromits orthopaedic product line and to achieve specified milestones, both of which will depend on itspreclinical, clinical, regulatory, manufacturing and sales and marketing capabilities or, where appropriate,its ability to enter into satisfactory arrangements with third parties to provide those functions. We may not be successful in developing these capabilities or entering into agreements with third parties on favorable terms. Further, our reliance upon third parties for these capabilities could reduce our control over such activities and could make us dependent upon these parties. Our inability to develop or contract for these capabilities would significantly impair our ability to develop and commercialize products.

• We are highly dependent on several principal members of our management and scientific staff. The loss of key personnel could have a material adverse effect on Therics’ business and results of operations, and could inhibit product development, commercialization and sales and marketing efforts. In addition, recruiting and retaining qualified scientific personnel to perform future R&D work is critical to our success. Competition for experienced scientists is intense. Failure to recruit and retain executive management and sales and marketing and scientific personnel on acceptable terms could prevent us from achieving our business objectives.

• The patent positions of biotechnology firms generally are highly uncertain and involve complex legal andfactual questions that can determine who has the right to develop a particular product. No clear policy has emerged regarding the breadth of claims covered by biotechnology patents in the United States. The biotechnology patent situation outside the United States is even more uncertain and is currently undergoing review and revision in many countries. Changes in, or different interpretations of, patent laws in the United States and other countries might allow others to use our discoveries or to develop and commercialize our products without any compensation to us.

25

Item 3. Quantitative and Qualitative Disclosures About Market Risk

        See discussion under “Quantitative and Qualitative Disclosures About Market Risk” beginning on page 22.

Item 4. Controls and Procedures.

        Pursuant to Rule 13a-15(b) under the Securities Exchange Act of 1934, we carried out an evaluation, with the participation of our management, including ourprincipal executive officer and principal financial officer, of the effectiveness of our disclosure controls and procedures (as defined under Rule 13a-15(e) under the Securities Exchange Act of 1934) as of the end of the period covered by this report. Based upon that evaluation, ourprincipal executive officer and principal financial officer concluded that our disclosure controls and procedures are effective in timely alerting them to material information relating to Tredegar required to be included in ourperiodic SEC filings.

        There has been no change in our internal control over financial reporting during the quarter ended September 30, 2003, that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

26

PART II - OTHER INFORMATION

Item 6. Exhibits and Reports on Form 8-K.

(a) Exhibit Nos.

4 Credit Agreement, dated as of October 17, 2003, by and among Tredegar Corporation, as borrower, its domestic subsidiaries, as guarantors, and the lenders (Wachovia Bank, National Association, as administrative agent, SunTrust Bank, as syndication agent, and Bank of America, N.A., as documentation agent)

31.1 Certification of Norman A. Scher, President and Chief Executive Officer of Tredegar Corporation, pursuant to Rules 13a-14(a) and 15d-14(a) promulgated under the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

31.2 Certification of D. Andrew Edwards, Vice President, Chief Financial Officer and Treasurer (Principal Financial Officer) of Tredegar Corporation, pursuant to Rules 13a-14(a) and 15d-14(a) promulgated under the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

32.1 Certification of Norman A. Scher, President and Chief Executive Officer of Tredegar Corporation, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

32.2 Certification of D. Andrew Edwards, Vice President, Chief Financial Officer and Treasurer (Principal Financial Officer) of Tredegar Corporation, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

(b) Reports on Form 8-K.

On July 21, 2003, we furnished a Form 8-K with respect to our second quarter 2003 earnings press release dated July 21, 2003. On October 21, 2003, we furnished a Form 8-K with respect to our third quarter 2003 earnings press release dated October 21, 2003.

27

SIGNATURES

        Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

Date:  November 13, 2003 Tredegar Corporation
(Registrant)


/s/ D. Andrew Edwards
——————————————————
D. Andrew Edwards
Vice President, Chief Financial Officer
and Treasurer
(Principal Financial and Accounting Officer

28